GET DAILY SIGNALSAquestive Therapeutics AQST Reports Q3 2026 Revenue Miss Amid Anaphylm NDA Progress
Key Takeaways
- Aquestive Therapeutics reported third-quarter 2026 revenue of $7.5 million, down 41.5% year over year and well below the consensus estimate of roughly $11.0 million.
- GAAP net loss per share was $0.18, missing the analyst consensus of a $0.12 loss per share.
- Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million a year earlier.
- The company resubmitted its Anaphylm New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the quarter, a key regulatory milestone.
- Aquestive reaffirmed its full-year 2026 guidance of $46 million to $50 million in revenue and a non-GAAP adjusted EBITDA loss of $30 million to $35 million.
Earnings Context and Why It Matters
Aquestive Therapeutics is a specialty biopharmaceutical company built around its proprietary oral-film delivery technology, with investors focused primarily on the progress of its lead pipeline candidate, Anaphylm, a sublingual film being developed for severe allergic reactions including anaphylaxis. The third quarter carried outsized weight because management had guided toward resubmitting the Anaphylm NDA during the period following an earlier Complete Response Letter from the FDA. Quarterly revenue remains secondary to the regulatory story, but a sharp year-over-year decline and a sizeable miss versus consensus still matter, because they signal the commercial and royalty mix that will fund the company's launch ambitions and cash runway ahead of a potential approval. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Aquestive Therapeutics reported total revenue of $7.5 million, a 41.5% decline from $12.8 million in the prior-year period and below the consensus estimate of approximately $11.0 million. The net loss per share was $0.18 on a GAAP basis, compared with a loss of $0.14 a year ago and versus the consensus expectation of a $0.12 loss. Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million in the same quarter last year. Cash and cash equivalents stood at $90.3 million at quarter-end, down from $121.2 million at the end of 2025.
Operationally, the company resubmitted the Anaphylm NDA in the third quarter, a milestone that management has described as central to its strategy. In October, after the quarter closed, Aquestive completed an out-licensing transaction for Libervant, providing $10 million in upfront, non-dilutive capital plus up to $47.5 million in potential regulatory and sales-based milestones and mid-teens royalties on net sales.
Market Reaction and Investor Sentiment
Shares of Aquestive Therapeutics traded lower in after-hours activity following the release, with the stock falling roughly 2.6% to around $3.78 after closing at $3.88. The stock has declined approximately 39% to 42% since the start of 2026, underperforming the broader market by a wide margin. Investor sentiment remains anchored to the Anaphylm regulatory timeline rather than near-term revenue, but the revenue miss and widening adjusted EBITDA loss reinforced concerns about the company's cash position and the time required to reach a potential commercial launch. The October Libervant licensing deal and the completed NDA resubmission are likely to be read as positive offsets, though the market's immediate reaction suggests caution around execution and capital requirements.
Forward Outlook and Key Factors to Monitor
The most important catalyst ahead is the FDA's review of the resubmitted Anaphylm NDA. Management has indicated that the base case assumes a six-month review clock, though it has also suggested the limited scope of the resubmission package could support a faster timeline. The timing and outcome of that review will define the company's commercial trajectory.
Investors should also watch how the October Libervant out-licensing transaction contributes to future quarters. The $10 million upfront payment and the potential for additional milestone and royalty income offer non-dilutive capital that could ease funding pressure as the company prepares for a potential Anaphylm launch.
Cash management remains a key theme. With $90.3 million in cash at quarter-end and a full-year adjusted EBITDA loss still guided to between $30 million and $35 million, the path to launch will depend on access to committed funding tied to regulatory milestones. Finally, coverage and reimbursement efforts for Anaphylm, if approved, will be an important watch item, as the company has acknowledged that payer access and physician adoption will take time to establish in the epinephrine market.
Using AI Tools to Track Biotech Names Like AQST
In my own workflow, I turn to Tickeron’s AI-powered tools to quickly surface comparable names and monitor technical setups across the healthcare sector. The AI Screener helps filter for patterns, fundamentals, and volatility that can complement traditional earnings analysis, especially when regulatory events dominate the story for companies like Aquestive Therapeutics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AQST in downward trend: 10-day moving average crossed below 50-day moving average on October 08, 2026
The 10-day moving average for AQST crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQST as a result. In 69 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
AQST moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for AQST entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AQST's RSI Oscillator exited the oversold zone, 29 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 66 cases where AQST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +6.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in 209 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AQST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.362) is normal, around the industry mean (8.029). P/E Ratio (-5.712) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (10.730) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. AQST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer thin film pharmaceutical and over the counter drug products
Industry PharmaceuticalsGeneric
Advertisement